ES2591355T3 - Uso novedoso de leflunomida y malononitrilamidas - Google Patents

Uso novedoso de leflunomida y malononitrilamidas Download PDF

Info

Publication number
ES2591355T3
ES2591355T3 ES11754832.1T ES11754832T ES2591355T3 ES 2591355 T3 ES2591355 T3 ES 2591355T3 ES 11754832 T ES11754832 T ES 11754832T ES 2591355 T3 ES2591355 T3 ES 2591355T3
Authority
ES
Spain
Prior art keywords
compound
leflunomide
esters
compounds
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11754832.1T
Other languages
English (en)
Spanish (es)
Inventor
Guido Koopmans
Birgit Hasse
Stefan Müllner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algiax Pharmaceuticals GmbH
Original Assignee
Algiax Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algiax Pharmaceuticals GmbH filed Critical Algiax Pharmaceuticals GmbH
Application granted granted Critical
Publication of ES2591355T3 publication Critical patent/ES2591355T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES11754832.1T 2010-08-24 2011-08-23 Uso novedoso de leflunomida y malononitrilamidas Active ES2591355T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37645310P 2010-08-24 2010-08-24
EP10008802 2010-08-24
US376453P 2010-08-24
EP10008802 2010-08-24
PCT/EP2011/004218 WO2012025217A1 (en) 2010-08-24 2011-08-23 Novel use of leflunomide and malononitrilamides

Publications (1)

Publication Number Publication Date
ES2591355T3 true ES2591355T3 (es) 2016-11-28

Family

ID=44587762

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11754832.1T Active ES2591355T3 (es) 2010-08-24 2011-08-23 Uso novedoso de leflunomida y malononitrilamidas

Country Status (7)

Country Link
US (1) US8957098B2 (cg-RX-API-DMAC10.html)
EP (1) EP2608782B1 (cg-RX-API-DMAC10.html)
JP (1) JP5820476B2 (cg-RX-API-DMAC10.html)
CN (1) CN103153295A (cg-RX-API-DMAC10.html)
DK (1) DK2608782T3 (cg-RX-API-DMAC10.html)
ES (1) ES2591355T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012025217A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034890T2 (hu) * 2010-10-29 2018-03-28 Algiax Pharmaceuticals Gmbh Malononitrilaminok alkalmazása neuropathiás fájdalomban
ES2984690T3 (es) * 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU649421B2 (en) 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
NZ589307A (en) 2008-04-29 2012-04-27 Pharnext Compositions comprising baclogen or terbinafine for treating alzheimer disease and related disorders through a modulation of angiogenesis
EP2314291A1 (en) * 2009-10-22 2011-04-27 Sanofi-Aventis Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis

Also Published As

Publication number Publication date
CN103153295A (zh) 2013-06-12
US20130274301A1 (en) 2013-10-17
EP2608782A1 (en) 2013-07-03
US8957098B2 (en) 2015-02-17
EP2608782B1 (en) 2016-06-29
JP2013536209A (ja) 2013-09-19
DK2608782T3 (en) 2016-09-05
JP5820476B2 (ja) 2015-11-24
WO2012025217A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
JP6054868B2 (ja) Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
CL2018000036A1 (es) Derivados etinilo
JP2013010793A5 (cg-RX-API-DMAC10.html)
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
WO2012107498A4 (en) Lysine demethylase inhibitors for myeloproliferative disorders
JP2016528180A5 (cg-RX-API-DMAC10.html)
JP2015537020A5 (cg-RX-API-DMAC10.html)
HRP20210344T1 (hr) Pripravci i postupci liječenja poremećaja cns
EA201591078A1 (ru) Пептиды в качестве агонистов окситоцина
JP2013010792A5 (cg-RX-API-DMAC10.html)
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20140966A1 (es) Quinazolincarboxamida azetidinas
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
MY193754A (en) Treatment for parkinson's disease
MX2012003720A (es) N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos.
PY2018921A (es) Agentes antiproliferativos para el tratamiento de pah
EA201692488A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
AU2016356504B2 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
ES2676198T3 (es) Derivados amino-quinoxalina para el tratamiento de enfermedades neurodegenerativas
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
AR104863A1 (es) Derivados imidazol
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
AR084516A1 (es) Moduladores de receptores de glutamato metabotropicos
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity